Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Without Concurrent Surufatinib in Neoadjuva

Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Without Concurrent Surufatinib in Neoadjuvant Therapy for Mid-to-low Localized Rectal Cancer of High-risk Criteria is a phase 2/3, interventional study registered as NCT07505472 by The First Hospital of Jilin University, with a registry enrolment figure of 212 participants, started 2026-02-23 and due to reach its primary completion in 2029-12-31. Interventions recorded: Experimental Group; Control group. Conditions listed: Rectal Cancer. Primary outcome: pathologic complete response，pCR. Colorectal eligibility wording from the registry: "Pathologically confirmed rectal tubular adenocarcinoma; Differentiation into Grade 1-3, i". Sites: China. No results are recorded here; the registry entry is the source.